Tagged with diagnostics,

Singapore In 2020, the FDA granted its first approval to a comprehensive liquid biopsy, potentially representing a paradigm shift towards using liquid biopsies upfront as an easier, safer, faster, and more effective tool for diagnosing cancer patients than traditional invasive tissue biopsies.   The company behind the Guardant360® CDx test, Guardant…

Singapore Simranjit Singh highlights Guardant Health’s role in the global precision oncology landscape and how the company leverages its proprietary blood tests, vast data sets, and advanced analytics across the huge AMEA region. Singh also touches on the significance of a recent US FDA approval for its comprehensive liquid biopsy and…

APAC COVID-19 has pushed diagnostics to the forefront of healthcare conversations across the world. Here, three leading lights from the Asia-Pacific medtech industry weigh in on what the new diagnostics paradigm might look like as the pandemic recedes.   Sanjay Prabhakaran, president Asia Pacific, Hologic “One positive outcome of this pandemic…

Singapore Regulatory harmonisation for medical devices between countries in Asia-Pacific has long been a challenging issue, predominantly due to the extreme variation in cultures, economic development, governmental models, and healthcare systems in the region.   Greater harmonisation would allow solutions introduced in APAC’s most developed markets to filter down to its…

Singapore Medtech industry veteran Sanjay Prabhakaran outlines the footprint and strategy of women’s health specialist Hologic in the dynamic Asia-Pacific region, how it leveraged its molecular diagnostics expertise to pivot towards COVID-19 diagnostics tests in 2020, and the leadership lessons he has learned from a 30-year corporate career with US multinationals.…

Asia-Pacific At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems in APAC means that a region accounting for 60 percent of the world’s population only represents a quarter of global…

Singapore Lance Little, managing director for Roche Diagnostics in Asia Pacific and board member of the Asia Pacific Medical Technology Association (APACMed), shares how COVID has affected their business in the region, his changing priorities during these challenging times, and the importance of building a unified culture across the regional organization,…

Singapore Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue analysis focused on the diagnosis of fibrosis and cancer, and his thoughts on the Singaporean healthcare start-up ecosystem.   We…

Norway Roche Diagnostics Norway’s Daniel Malarek discusses the resurgence of diagnostics in the wake of the COVID-19 pandemic, the Norwegian approval process for diagnostic tools, and the importance of stakeholder education.   Research shows that more than 70 percent of medical decision-making requires some form of diagnostics, yet less than 2…

Diagnostics Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their offerings through R&D.  Cho also compares the challenges of the Chinese market with the potential in the Indian market and offers his opinion on the role of diagnostics in post Covid-19 healthcare.   There is…

Precision Medicine With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region must be addressed effectively, quickly and comprehensively. Who better to accomplish that than the Asian companies on the ground, closest…

Korea Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian patients, explores the company’s expansion plans into China, Japan, and Southeast Asia, and the synergies in their partnerships with big…